CODX
New York, new networking speedrun
Co-Diagnostics is heading into United Nations General Assembly week like a startup at a conference with unlimited coffee: lots of meetings, lots of handshakes, and hopefully a few real leads. The company said it will participate in global health events during the week, keeping its name in the room as policymakers, NGOs, and health groups gather in New York.
Why investors should care
This isn’t an FDA approval, a giant contract, or a glossy revenue guide-up. It’s more of a visibility play — the kind of thing companies do when they want to stay close to the people who influence testing priorities, public health spending, and future partnerships.
In other words:
- good for keeping Co-Diagnostics relevant in global health circles
- potentially useful for business development
- not, by itself, the sort of news that usually sends a stock sprinting
Big picture
If these events lead to actual agreements, deployments, or funding opportunities, then today’s announcement starts looking a lot more interesting. If not, it’s still a decent reminder that small-cap biotech lives and dies by relationship-building as much as product data. Big picture: the real money is in what happens after the panel discussion, not during the panel discussion.